Abstract：Objective: To analyze the diagnostic efficacy of mirna-192-5p in multiple myeloma and the relationship between mirna-192-5p and clinical parameters. Methods: From May 2016 to may 2019, 90 patients with multiple myeloma treated in our hematology and oncology department were selected as the myeloma group, and 60 normal control group as the healthy people who came to our hospital for physical examination at the same time. The content of mirna-192-5p in the serum of patients with multiple myeloma and normal people was detected by fluorescence quantitative PCR, and the content of mirna-192-5p in the serum of multiple myeloma was analyzed by ROC curve. The correlation between mirna-192-5p and clinical parameters in patients with multiple myeloma was analyzed by Pearson correlation. Results: The expression level of mirna-192-5p was 0.72 ± 0.11 in the serum of patients with multiple myeloma and 1.08 ± 0.15 in the serum of normal control group, with statistical difference between the two groups (P<0.05); The analysis of ROC curve showed that the area under the curve of mirna-192-5p in the diagnosis of multiple myeloma was 0.653, the cutoff value is 0.68, the sensitivity was 77%, the specificity was 56%, P = 0.023; in β2-MG The content of mirna-192-5p in the serum of patients with high G content was significantly lower than that of patients with normal β 2-mg content (P<0.05). The content of mirna-192-5p in the serum of patients with high creatinine level was also significantly lower than that of patients with normal creatinine level (P<0.05). The content of mirna-192-5p in the serum of patients with low hemoglobin and albumin was significantly lower than that of patients with normal level (P<0.05). The content of mirna-192-5p was negatively correlated with the content of IgG and IgA respectively (r = -0.457, - 0.615, P<0.05). Conclusion: Mirna-192-5p has abnormal low expression in the serum of patients with multiple myeloma. It can only be used as an auxiliary diagnostic standard in the diagnosis of multiple myeloma. It has a certain correlation with disease stage and prognosis related indicators. It is a good marker in the progress monitoring of multiple myeloma.
[1] Morawska M,Grzasko N,Kostyra M,et al.Therapy-related peripheral neuropathy in multiple myeloma patients[J].Hematological Oncology,2016,33(4):113~119. [2] Berenson J R,Crowley J J,Grogan T M,et al.Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.[J].Blood,2016,99(9):3163~3168. [3] Lonial S,Weiss B M,Usmani S Z.Daratumumab monotherapy in patients with treatment-refractory multiple myeloma(SIRIUS)an open-label,randomised,phase 2 trial.[J].Lancet,2016,387(10027):1551~1560. [4] Nicole L,Petra L,Kurt B,et al.Distribution of miRNA expression across human tissues:[J].Nucleic Acids Research,2016,44(8):3865~3877. [5] Zhou X,Huang Z,Xu L,et al.A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer[J].Oncotarget,2016,7(43):69616~69624. [6] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2015年修订)[J].中华内科杂志,2015,54(12):1066~1070. [7] Tong L I,Wang H T,Liu Z G,et al.CAR Technology and Its Application in Treatment of Multiple Myeloma[J].Journal of Experimental Hematology,2016,24(1):279~284. [8] Ezponda T,Duperericher D,Will C M,et al.UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition[J].Cell Reports,2017,21(3):628~640. [9] Wang G M,Yang G Z,Huang Z X,et al.A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma[J].China Medical Abstracts,2017,56(7):500~506. [10] Gong J,Tian J,Lou J,et al.A functional polymorphism in lnc-LAMC2-1:1 confers risk of colorectal cancer by affecting miRNA binding[J].Carcinogenesis,2016,37(5):443~451.
2020, Vol. 26 
冀公网安备13080202000677号